Protein A potentiates lymphokine-activated killer cell induction in normal and melanoma patient lymphocytes

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Lymphokine-activated killer (LAK) cells are crucial for anti-tumor immunity.
• Protein A from Staphylococcus aureus is known to modulate immune responses.
• Melanoma patients often exhibit compromised immune function.

Purpose of the Study:

• To investigate the synergistic effects of Protein A and Interleukin-2 (IL-2) on LAK cell induction and activity.
• To evaluate the impact of this combination on both normal and melanoma patient lymphocytes.
• To explore the potential of this regimen for cancer immunotherapy.

Main Methods:

• Peripheral blood mononuclear cells (PBMC) from healthy donors and melanoma patients were co-cultured with varying doses of Protein A and a fixed concentration of IL-2.
• LAK cell-mediated cytotoxicity was assessed against NK-sensitive (K-562) and NK-resistant (M14) tumor cell lines.
• DNA synthesis in PBMC was measured after 4 days of culture.

Main Results:

• Co-culture with Protein A and IL-2 demonstrated a synergistic effect, significantly enhancing LAK cell cytotoxicity.
• Increased cytotoxic and lytic potential of LAK cells was observed against both sensitive and resistant tumor cells.
• Protein A and IL-2 co-culture also potentiated DNA synthesis in PBMC, indicating immune cell proliferation.

Conclusions:

• Low-dose Protein A and IL-2 combination effectively potentiates LAK cell induction and activity.
• This synergistic effect holds promise for developing novel LAK-based immunotherapy strategies for cancer patients.
• The findings suggest a potential therapeutic approach for enhancing anti-tumor immune responses in melanoma and other cancers.